Xerostomie – Ätiologie, Klinik, Diagnostik und Therapie

Xerostomie ist ein Krankheitsbild, mit dem der praktisch tätige Zahnarzt zunehmend konfrontiert wird. Die Ursachen reichen von der Einnahme systemisch wirkender Medikamente bis hin zu Autoimmunerkrankungen; ebenso können die klinischen Symptome äußerst vielfältig sein. Aus diesen Gründen gestalten sich Diagnose und Therapie der Krankheit oft schwierig. In der vorliegenden Übersichtsarbeit soll ein Überblick über Ätiologie und Klinik der Xerostomie sowie über potenzielle Therapiekonzepte gegeben werden.

A steadily increasing number of people is suffering from xerostomia. The reasons for xerostomia are manifold, reaching from the side effects of systemic drugs to autoimmune diseases. The clinical manifestations may be manifold, too. Thus, diagnosis as well as treatment of xerostomia may be complex. The aim of this article is to give a review on the etiology and clinical manifestations of xerostomia as well as potential therapeutical concepts.

Schlüsselwörter:

Xerostomie - Sjögren–Syndrom - Speichelersatzmittel

Keywords

Xerostomia - Sjoegren's Syndrome - Saliva Substitute

Literatur

• 1 Al–Hashimi I.. The management of Sjögren's syndrome in dental practice.  J Am Dent Assoc. 2001;  132 1409-1417
• 2 Atkinson JC, Wu AJ.. Salivary gland dysfunction: causes, symptoms, treatment.  J Am Dent Assoc. 1994;  125 409-416
• 3 Brown LR, Dreizen SA, Daly TE.. Interrelations of oral microorganisms, immunoglobulins, and dental caries following radiotherapy.  J Dent Res. 1978;  57 882-893
• 4 Cassolato SF, Turnbull RS.. Xerostomia: clinical aspects and treatment.  Gerodontology. 2003;  20 64-77
• 5 Christersson CE, Lindh L, Arnebrant T.. Film–forming properties and viscosities of saliva substitutes and human whole saliva.  Eur J Oral Sci. 2000;  108 418-425
• 6 Dawes C.. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man.  J Dent Res. 1987;  66 648-653
• 7 Dreizen S, Brown LR, Handler S, Levy BM.. Radiation–induced xerostomia in cancer patients. Effect on salivary and serum electrolytes.  Cancer. 1976;  38 273-278
• 8 Epstein JB, Loh R, Stevenson–Moore P. et al. . Chlorhexidine rinse in prevention of dental caries in patients following radiation therapy.  Oral Surg Oral Med Oral Pathol. 1989;  68 401-405
• 9 Felst E, Dörner T, Hansen A.. Indikation und Option neuer immunmodulatorischer Therapien beim Sjögren–Syndrom.  Z Rheumatol. 2007;  66 679-685
• 10 Fox PC.. Management of dry mouth.  Dent Clin North Am. 1997;  41 863-876
• 11 Garg AK, Malo M.. Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy.  J Am Dent Assoc. 1997;  128 1128-1133
• 12 Gelhard TB, Fidler V, s'Gravenmade EJ, Vissink A.. Remineralization of softened human enamel in mucin– or CMC–containing artificial salivas.  J Oral Pathol. 1983;  12 336-341
• 13 Ghezzi EM, Lange LA, Ship JA.. Determination of variation of stimulated salivary flow rates.  J Dent Res. 2000;  79 1874-1878
• 14 Greenspan D, Daniels TE.. Effectiveness of pilocarpine in postradiation xerostomia.  Cancer. 1987;  59 1123-1125
• 15 Guchelaar HJ, Vermes A, Meerwaldt JH.. Radiation–induced xerostomia: pathophysiology, clinical course and supportive treatment.  Support Care Cancer. 1997;  5 281-288
• 16 Guggenheimer J, Moore PA.. Xerostomia: etiology, recognition and treatment.  J Am Dent Assoc. 2003;  134 61-69
• 17 Guijarro Guijarro B, López AF Sánchez, Hernández G. Vallejo. Treatment of Xerostomia. A review.  Med Oral. 2001;  6 7-18
• 18 Gupta A, Epstein JB, Sroussi H.. Hyposalivation in elderly patients.  J Can Dent Assoc. 2006;  72 841-846
• 19 Hatton MN, Levine MJ, Margarone JE. et al. . Lubrication and viscosity features of human saliva and commercially available saliva substitutes.  J Oral Maxillofac Surg. 1987;  45 496-499
• 20 Imfeld T.. Oligosialia and xerostomia. II. Diagnosis, prevention and treatment.  Schweiz Monatsschr Zahnmed. 1984;  94 1083-1096
• 21 Imfeld T.. Reduzierter Speichelfluß: Ursachen, Folgen und Diagnose. in: Reduzierter Speichelfluß und Mundtrockenheit: Herausforderung zur Zusammenarbeit in der Kariesprophylaxe. München: MSC Medizinischer Creativ Service GmbH 1995
• 22 Johnson JT, Ferretti GA, Nethery WJ. et al. . Oral pilocarpine for post–irradiation xerostomia in patients with head and neck cancer.  N Engl J Med. 1993;  329 390-395
• 23 Joyston–Bechal S, Kidd EA.. The effect of three commercially available saliva substitutes on enamel in vitro.  Br Dent J. 1987;  163 187-190
• 24 Kassan SS, Moutsopoulos HM.. Clinical ma– nifestations and early diagnosis of Sjogren syn– drome.  Arch Intern Med. 2004;  164 1275-1284
• 25 Keene HJ, Fleming TJ.. Prevalence of caries–associated microflora after radiotherapy in patients with cancer of the head and neck.  Oral Surg Oral Med Oral Pathol. 1987;  64 421-426
• 26 Kielbassa AM, Shohadai SP.. Die Auswirkungen von Speichelersatzmitteln auf die Läsionstiefe von demineralisiertem Schmelz.  Dtsch Zahnarztl Z. 1999;  54 757-763
• 27 Kielbassa AM, Meyer–Lückel H.. Die Auswirkungen von Speichelersatzmitteln und Mundspüllösungen auf Dentin.  Schweiz Monatsschr Zahnmed. 2001;  111 1060-1066
• 28 Kielbassa AM, Shohadai SP, Schulte–Mönting J.. Effect of saliva substitutes on mineral content of demineralized and sound dental enamel.  Support Care Cancer. 2001;  9 40-47
• 29 Le Veque FG, Montgomery M, Potter D. et al. . A multicenter, randomized, double–blind, placebo–controlled, dose–titration study of oral pilocarpine for treatment of radiation–induced xerostomia in head and neck cancer patients.  J Clin Oncol. 1993;  11 1124-1131
• 30 Levine MJ.. Artificial salivas: present and future.  J Dent Res. 1987;  66 693-698
• 31 Meyer–Lückel H, Kielbassa AM.. Die Verwendung von Speichelersatzmitteln bei Patienten mit Xerostomie.  Dtsch Zahnarztl Z. 2002;  57 335-344
• 32 Meyer–Lückel H, Schulte–Mönting J, Kielbassa AM.. The effect of commercially available saliva substitutes on predemineralized bovine dentin in vitro.  Oral Dis. 2002;  8 192-198
• 33 Meyer–Lückel H, Tschoppe P, Kielbassa AM.. Linseed based saliva substitutes and their effect on mineral dissolution of predemineralized bovine dentin in vitro.  J Dent. 2006;  34 751-756
• 34 Meyer–Lückel H, Kielbassa AM.. Influence of calcium phosphates added to mucin–based saliva substitutes on bovine dentin.  Quintessence Int. 2006;  37 537-544
• 35 Meyer–Lückel H, Chatzidakis AJ, Kielbassa AM.. Effect of various calcium/phosphates ratios of carboxymethylcellulose–based saliva substitutes on mineral loss of bovine enamel in vitro.  J Dent. 2007;  35 851-857
• 36 Momm F, Volegove–Neher NJ, Schulte–Mönting J. et al. . Different saliva substitutes for treatment of xerostomia following radiotherapy.  Strahlenther Onkol. 2005;  181 231-236
• 37 Mühlemann HR.. Das Verhalten von Kiefer und Zähnen bei der Radiotherapie von malignen Tumoren der Mundhöhle und des Pharynx.  Schweiz Monatsschr Zahnmed. 1945;  55 641-688
• 38 Nagy K, Urban E, Fazekas O. et al. . Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer.  J Craniofac Surg. 2007;  18 1157-1164
• 39 Nederfors T, Isaksson R, Mörnstad H. et al. . Prevalence of perceived symptoms of dry mouth in an adult Swedish population: relation to age, sex and pharmacotherapy.  Community Dent Oral Epidemiol. 1997;  25 211-216
• 40 Scully C.. Drug effects on salivary glands: dry mouth.  Oral Dis. 2003;  9 165-176
• 41 Scully C, Felix DH.. Oral medicine – update for the dental practitioner. Dry mouth and disorders of salivation.  Br Dent J. 2005;  199 423-427
• 42 Ship JA, Pillemer SR, Baum BJ.. Xerostomia and the geriatric patient.  J Am Geriatr Soc. 2003;  50 535-543
• 43 Smith RG, Burtner AP.. Oral side–effects of the most frequently prescribed drugs.  Spec Care Dentist. 1994;  14 96-102
• 44 Sreebny LM, Schwarts SS.. A reference guide to drugs and dry mouth.  Gerodontology. 1986;  5 75-99
• 45 Stratmann U, Mokrys K.. Mundtrockenheit – Ursachen und Symptomatik.  Zahnarztl Mitt. 2000;  90 62-64
• 46 Tenovuo J, Lumikari M, Soukka T.. Salivary lysozyme, lactoferrin and peroxidases: antibacterial effects on cariogenic bacteria and clinical applications in preventive dentistry.  Proc Finn Dent Soc. 1991;  87 197-208
• 47 Tschoppe P, Meyer–Lueckel H, Toll R. et al. . In vitro analysis of a new saliva substitute (Saliva natura) on enamel and dentin.  Laryngorhinootologie. 2007;  86 723-727
• 48 Turner MD, Ship JA.. Dry mouth and its effect on the oral health of elderly people.  J Am Dent Assoc. 2007;  138 15-20
• 49 van der Reijden WA, van der Kwaak H, Vissink A. et al. . Treatment of xerostomia with polymer–based saliva substitutes in patients with Sjögren`s syndrome.  Arthritis Rheum. 1996;  39 57-63
• 50 van der Reijden WA, Vissink A, Veerman EC. et al. . Treatment of oral dryness related complaints (xerostomia) in Sjögren`s syndrome.  Ann Rheum Dis. 1999;  58 465-474
• 51 Ventafridda V, De F Conno, Ripamonti C. et al. . Quality–of–life assessment during a palliative care programme.  Ann Oncol. 1990;  1 415-420
• 52 Wiseman LR, Faulds D.. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia.  Drugs. 1995;  49 143-155
• 53 Wolpert E, Jung F, Middelhoff HD. et al. . Treatment of drug–induced dryness of mouth in psychiatric patients – a controlled comparative study.  Fortschr Neurol Psychiatr Grenzgeb. 1980;  48 224-233
• 54 Wynn RL, Meiller TF.. Artificial saliva products and drugs to treat xerostomia.  Gen Dent. 2000;  48 630-636

Korrespondenzadresse